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Abstract
Introduction: Novel adjuvant therapies are needed to prevent metastatic relapses in HER2-expressing breast
cancer. Here, we tested whether trastuzumab-selected single-chain Fv (scFv) could be used to develop an anti-
idiotype-based vaccine to inhibit growth of HER2-positive tumor cells in vitro and in vivo through induction of
long-lasting HER-specific immunity.
Methods: BALB/c mice were immunized with anti-trastuzumab anti-idiotype (anti-Id) scFv (scFv40 and scFv69), which
mimic human HER2. Their sera were assessed for the presence of HER2-specific Ab1’ antibodies and for their ability to
reduce viability of SK-OV-3 cells, a HER2-positive cancer cell line, in nude mice. MMTV.f.huHER2(Fo5) transgenic mice
were immunized with scFv40 and scFv69 and, then, growth inhibition of spontaneous HER2-positive mammary tumors,
humoral response, antibody isotype as well as splenocyte secretion of IL2 and IFN-g were evaluated.
Results: Adoptively-transferred sera from BALB/c mice immunized with scFv40 and scFv69 contain anti-HER2 Ab1’
antibodies that can efficiently inhibit growth of SK-OV-3 cell tumors in nude mice. Similarly, prophylactic
vaccination with anti-Id scFv69 fully protects virgin or primiparous FVB-MMTV.f.huHER2(Fo5) females from
developing spontaneous mammary tumors. Moreover, such vaccination elicits an anti-HER2 Ab1’ immune response
together with a scFv69-specific Th1 response with IL2 and IFN-g cytokine secretion.
Conclusions: Anti-trastuzumab anti-Id scFv69, used as a therapeutic or prophylactic vaccine, protects mice from
developing HER2-positive mammary tumors by inducing both anti-HER2 Ab1’ antibody production and an anti-
HER2 Th2-dependent immune response. These results suggest that scFv69 could be used as an anti-Id-based
vaccine for adjuvant therapy of patients with HER2-positive tumors to reverse immunological tolerance to HER2.
Introduction
Breast cancer affects women worldwide and is a major
public health problem. Despite progress in the field of
surgery and adjuvant therapies, the risk of metastatic
relapse remains high. Human Epidermal growth factor
Receptor 2 (HER2) over-expression is observed in
approximately 20% of invasive breast cancer and is an
independent predictor of survival as it is associated with
poor prognosis, aggressive disease and resistance to
chemotherapy and hormone therapy [1-4]. HER2 has
been targeted with immunotherapeutic approaches based
on the use of anti-HER2 monoclonal antibodies (mAb),
tyrosine kinase inhibitors and cancer vaccines [5].
Patients with HER2-expressing tumors show HER2-specific
humoral and/or T-cell responses [6,7]. Such anti-HER2
immune responses, albeit of low magnitude, indicate that
HER2 is a suitable candidate for HER2-targeted vaccine
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any medium, provided the original work is properly cited.strategies. Induction of a stronger HER2-specific immunity
with anti-tumor vaccines should lead to the establishment of
immune memory, thereby preventing tumor recurrence,
metastasis and relapse. However, HER2-induced immunolo-
gical tolerance has been described, probably related to its
oncofetal origin, which is an obstacle to efficient vaccination
against this antigen [8]. To circumvent self antigen-depen-
dent tolerance, peptide-, DNA- or anti-Idiotype (Id)-based
vaccines have been developed that show great specificity
without notable toxicity [9-14]. Among them, anti-Id antibo-
dies have been proposed as vaccines for cancer immunother-
apy and significant success has been achieved using anti-Id
vaccines mimicking tumor-associated antigens (TAAs). This
approach is based on N.K. Jerne’s idiotype network theory
about the Ab1-Ab2-Ab3 antibody cascade stimulation,
whereby specific anti-Id antibodies (Ab2b induced by immu-
nization with antigen-specific Ab1 antibodies, can serve as an
“internal image” of the target antigen and can be used to
induce Ab3 (also named Ab1’) antibodies that can bind to the
cognate antigen [15]. Previous studies have described the use
in solid tumors of anti-Id mAbs, which mimic TAAs, such as
carcinoembryonic antigen (CEA), disialoganglioside GD2 or
cancer-antigen 125 (CA-125), and demonstrated that these
anti-Id mAbs induce an antigen-specific humoral response
[16-19]. In clinical trials, including patients with ovarian carci-
noma, colorectal carcinoma or malignant melanoma, anti-Id-
specific humoral and/or cellular responses following immuni-
zation were associated with a better survival rate without toxi-
city, but with modest objective responses. Available results of
treatment of breast cancer patients with anti-Id mAbs are still
very preliminary and conclusions go no further than the mere
biologic proof of principle [20].
In this context, our goal was to develop a vaccine to
boost anti-HER2 immunity in patients with HER2-posi-
tive tumors and pre-existent low-level immunity. To this
end, the use of HER2-mimicking anti-Id antibodies as a
vaccine is a promising alternative. In a previous work
[21], we reported that two human anti-Id scFv antibody
fragments (scFv40 and scFv69), which were selected by
screening a phage-displayed library using the anti-HER2
antibody trastuzumab, induced an anti-HER2 antibody
response in sera of immunized BALB/c mice. In the pre-
sent study, we show that immunization with anti-Id
scFv40 and scFv69 induces production of Ab1’ that inhi-
bit growth of HER2-positive tumor cells both in vitro and
in vivo. Moreover, prophylactic vaccination with anti-Id
scFv69 efficiently protects MMTV.f.huHER2(Fo5) mice
from developing spontaneous HER2 positive mammary
tumors through the induction of a HER2-specific Ab1’
antibody response. Taken together, these results indicate
that the anti-Id scFv69 fragment could be envisaged as
an anti-idiotype-based vaccine for adjuvant therapy in
patients with HER2-positive tumors, through reversion of
HER2-specific immunological tolerance.
Materials and methods
Reagents
The recombinant HER2-Fc fusion protein (kindly pro-
vided by Pr. J.P. Mach, Biochemistry Institute, University
of Lausanne, Switzerland) is composed of two extracel-
lular domains of human HER2 linked with a human Fc
fragment and was produced by transfection of Human
Embryonic Kidney 293 cells. The anti-HER2 humanized
antibody trastuzumab (Herceptin
®)w a sp u r c h a s e df r o m
Genentech, Inc. (San Francisco, CA, USA). Production,
purification and characterization of anti-Id trastuzumab-
selected scFv40 and scFv69 have already been described
[21]. The irrelevant scFv 13R4 is a kind gift from Dr. P.
Martineau (IRCM, Montpellier, France). MFE23-Fc
fusion protein is a kind gift from R. Kontermann (Uni-
versity of Stuttgart, Germany).
Cell lines
The HER2-overexpressing human ovarian carcinoma
cell line SK-OV-3 and the Chinese hamster ovarian
(CHO) cell line, were obtained from the American Type
Culture Collection (ATCC; Rockville, MD, USA). SK-
OV-3 cells were cultured in DMEM medium (Gibco,
Paisley, UK) and CHO cells in RPMI-1640 medium
(Gibco), both supplemented as recommended by ATCC.
Cells were maintained at 37°C in a humidified atmo-
sphere with 5% CO2.
Mice
All in vivo experiments were performed in compliance
with the French guidelines for experimental animal stu-
dies (Agreement N° B34-172-27). Six-to eight-week-old
female BALB/c, FVB (the mouse strain used to generate
the MMTV.f.huHER2(Fo5) transgenic line) and nude
athymic nude mice were purchased from Harlan
Laboratories (Germany). The transgenic mouse line
MMTV.f.huHER2(Fo5) was obtained from Genentech
and has been previously described [22]. These mice,
which over-express human HER2 under the control of
the MMTV promoter and spontaneously develop mam-
mary tumors within an average time of seven months
from birth, are used as a pre-clinical model of HER2-
overexpressing breast cancer. They were maintained in
the IRCM animal facilities and used for immunization
when they were three-month-old. For in vivo experi-
ments, body weight was assessed weekly, as a surrogate
marker of toxicity for the duration of the experiments,
concomitantly with tumor measurement.
Anti-Id scFv mouse immunization
Immunogens were first injected subcutaneously (s.c.)
after emulsion with Complete Freund Adjuvant (CFA)
in BALB/c, FVB or MMTV.f.huHER2(Fo5) mice, fol-
lowed two weeks later by a second s.c. administration
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intraperitoneal (i.p.) injections with IFA were given at
day 21 and 35 after the initial boost. In FVB-MMTV.f.
huHER2(Fo5) mice, a final i.p. injection with IFA was
given at Day 90 after the initial boost. Immunogens
were anti-Id scFv40 and scFv69 (50 μg/inj), HER2-Fc
fusion protein (20 μg/inj), or phosphate-buffered saline
PBS (negative control) at a 1:1 ratio with CFA or IFA.
For serum antibody measurements, mice were bled and
sera were drawn from the tail vein at various times dur-
ing the experiment and stored at -20°C until assay.
ELISA and flow cytometry analysis of HER2-specific Ab1’
antibodies in sera of vaccinated mice
Indirect ELISA and flow cytometry analysis were per-
formed, as previously described [21], to detect the pre-
sence of anti-HER2 antibodies (Ab1’)i ns e r ao f
immunized mice. Briefly, indirect ELISA was performed
by coating 96-well plates overnight at 4°C with HER2-Fc
fusion protein diluted at 5 μg.ml
-1 in PBS and then satu-
rated for one hour with PBS containing 1% serum albu-
min (BSA). After four washings with 0.1% Tween/PBS,
100 μl of diluted sera (1:50) from immunized mice were
added to each well and incubated for 1.5 h at room
temperature. Secondary goat anti-mouse IgG (g-chain
specific)-horseradish conjugate (Millipore Chemicon,
Billerica, MA, USA) was added (dilution 1:2,500) after
plate washing, incubated for 1.5 h, and then ο-phenyle-
nediamine substrate was added for revelation according
to the supplier’s instructions (Sigma, St Louis, MO,
USA). After stopping the reaction with 50 μlo f3 N
HCl/well, absorbance was measured at 490 nm, using an
ELISA microreader (Multiskan EX, Thermo Electron
Corporation, Vantaa, Finland).
For flow cytometry analysis, SK-OV-3 and CHO cells
were incubated for one hour at 4°C with 100 μlo fe a c h
mouse serum (diluted at 1:50) or 100 μl of trastuzumab
(at 20 μg/ml) diluted in PBS containing 10% fetal calf
serum. After washing, cells w e r ei n c u b a t e da t4 ° Cw i t h
either 100 μl of sheep anti-mouse IgG-FITC-labeled
antibody (1:100; Sigma-Aldrich, Saint Louis, MO, USA)
for sera or anti-human-FITC-labeled antibody (1:100;
Sigma-Aldrich) for trastuzumab for 45 minutes. Cells
were then suspended in 500 μl PBS and 10,000 events
were analyzed with a FACScan apparatus (Becton Dick-
inson, Franklin Lakes, NJ, USA).
Stable transfection of SK-OV-3 cells with luciferase
To image tumor cells in nude mice, SK-OV-3 cells were
transfected with a luciferase-expressing vector (CMV-
L u c - H y g r o ) ,ag i f tf r o mD r .P .B a l a g u e r( U 8 9 6 ,I n s t i t u t
de Recherche en Cancérologie de Montpellier, France),
using a Calcium Phosphate transfection kit (Sigma).
Transfected cells (SK-OV-3-Luc) were selected with
400 μg/ml Hygromycin and individual clones were ana-
lyzed for luciferase expression by measuring luciferase
activity of cells plated in 96 well/plates with a lumin-
ometer (Microbeta, Perkin-Elmer Wallac, Waltham,
MA, USA). HER2 expression in SK-OV-3-Luc clones
was measured by flow cytometry with a FACScan flow
cytometer (Becton Dickinson, San Jose, CA, USA).
Cell viability
Sera from immunized BALB/c mice were harvested at
Day 42 after the initial boost, pooled, sterile-filtered and
stored at -20°C until use. HER2-specific antibodies were
detected in the serum as described above. A total of 1 ×
10
4 SK-OV-3-Luc cells/well were plated in 96-well
plates in 100 μl of culture medium and grown at 37°C
for 24 h. Thereafter, 100 μl of a 1:5 dilution of sera
f r o mi m m u n i z e dB A L B / cm i c ew e r ea d d e dt ot h ec u l -
ture medium. On Day 5, 50 μl of luciferin solution (Pro-
mega), at a final concentration of 3 × 10
-4 M, were
added to the cells and luminescence was measured with
a luminometer (Microbeta, Wallac). Cell number was
proportional to the emitted luminescence. The results
were normalized to the luminescence of non-treated
cells. Each condition was done in triplicate in two inde-
pendent experiments.
Adoptive transfer of immune sera from anti-Id scFv-
vaccinated mice
Female athymic nude mice were i.p. injected with 5 ×
10
5 SK-OV-3-Luc cells/mouse and grouped (n =5a n i -
mals/group) at Day 3 after injection. At Day 4 post-
graft, mice were i.p. injected with 200 μlo fm o u s e
s e r u mf r o mn a ï v ed o n o r s ,o rf r o mB A L B / cm i c ei m m u -
nized with anti-Id scFv40, anti-Id scFv69, or HER2-Fc
once a week for four weeks. Trastuzumab (200 μg/inj)
was used as a positive control of the experiment. Since
the tumor size is proportional to the emitted lumines-
cence, the efficiency of the different treatments was
evaluated by measuring the luminescence once a week
following i.p. injection of luciferin (100 μg/g). Mice were
sacrificed when tumors reached the luminescence level
of 3 × 10
7 photon/second. The results were expressed
by an adapted Kaplan-Meier survival curve, using the
time taken for a tumor to reach this level of emitted
luminescence. Moreover, a median delay was defined as
the time needed to 50% of the mice to reach that
luminescence.
In vivo prophylactic vaccination with anti-Id scFv40 or
anti-Id scFv69
MMTV.f.huHER2(Fo5) and FVB mice were immunized
following the vaccination schedule described above
when they were three months old. Follow-up of sponta-
neous development of mammary tumors was performed
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duration of the experiment. Results were expressed by an
adapted Kaplan-Meier curve of tumor-free survival using
the age of palpable tumor onset in each mice. Moreover,
the median delay was defined as the age when 50% of the
mice had developed palpable mammary tumors. The
study was ended at 59 weeks of age.
In vitro stimulation of splenocytes and analysis of IL2 and
IFNg production in culture supernatants
Six days after the final boost, the spleen of one immunized
MMTV.f.huHER2(Fo5) mouse from each group was
excised and pressed through stainless mesh. Isolated cells
were washed with RPMI medium and then erythrocytes
were lysed by hypotonic shock with 0.83% ammonium
chloride solution. Splenocytes (5 × 10
5 per well) were
seeded in flat-bottomed 96-well culture plates in triplicates
in the presence of scFv69 and HER2-Fc (2.0 μg/ml/each)
as stimulating agents. Mfe23-Fc fusion protein and
scFv13R4 (2.0 μg/ml/each) were used as irrelevant proteins
and 7.5 μg/ml Concanavalin A was used as a positive con-
trol. Cell-free supernatants were recovered 24 h and 72 h
post-stimulation and were analyzed for IL2 and IFN-g pro-
duction by using the ELISA kit (BD Biosciences, San José,
CA, USA) according to the manufacturer’s instructions.
Immunoglobulin isotyping
Isotype distribution of anti-scFv69- and -HER2-Fc speci-
fic antibodies generated in immunized MMTV.f.huHER2
(Fo5) and FVB mice was determined using a mouse
monoclonal isotyping kit (Pierce, Rockford, IL, USA)
according to the manufacturer’s instructions.
Statistical methods
Concerning the in vitro assays, comparison of the per-
centage of cell viability inhibition between the different
groups and normal mouse sera (NoMS) was performed
with the Wilcoxon two-sample exact test for all continu-
ous variables. The HER2-specific humoral responses in
mice immunized with PBS or with scFv69 were com-
pared with the Wilcoxon two-sample exact test. Differ-
ences were considered statistically significant when P <
0.05. Survival rates were estimated from the time of the
xenograft until the date of the event of interest using
the Kaplan-Meier method. Median survival was pre-
sented with 95% confidence intervals. The event of
interest was a bioluminescence value of 3 × 10
7 photon/
second for athymic nude mice and the appearance of
palpable mammary tumors for huHER2-transgenic mice.
Survival curves were compared using the Log-rank test.
Statistical analysis was performed using the STATA 10.0
software (StataCorp LP, College Station, TX, USA).
Results
Anti-Id immunization of BALB/c mice with scFv40 or
scFv69 induces anti-HER2 humoral Ab1’ immune response
To test whether the trastuzumab-specific anti-Id scFv40
a n ds c F v 6 9w ep r e v i o u s l yi s o l a t e dc o u l db eu s e dt o
develop a vaccine to boost anti-HER2 immunity, we
immunized six- to eight-week-old BALB/c mice (n =2 0
animals/group) with scFv40, scFv69, HER2-Fc fusion
protein, or PBS (negative control). HER2-specific antibo-
dies were detected by ELISA in pooled sera from the
different groups of immunized mice (Figure 1A). Specifi-
cally, scFv-induced anti-HER2-Ab1’ antibodies were
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Figure 1 Anti-HER2 antibodies are present in sera from BALB/c mice immunized with anti-Id scFv40 and scFv69. (A) ELISA of pooled
sera from mice (n = 20/group) immunized with scFv40, scFv69 or HER2-Fc. Values are presented as mean ± SD of the Absorbance at 490 nm
from three independent experiments. Flow cytometry analysis in (B) HER2-overexpressing SK-OV-3 and (C) HER2-negative CHO cells of the HER2-
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Day 42 post-immunization, and persisted throughout the
experiment (Day 94). As expected, anti-HER2 antibody
titers were higher in sera from animals immunized with
HER2-Fc (HER2-FcMS) than in sera from mice immu-
nized with scFv40 (scFv40MS) and scFv69 (scFv69MS).
This was partially due to an anti-Fc response, which cor-
responded to approximately 30% of the whole antibody
response in HER2-FcMS, as previously demonstrated by
ELISA using an irrelevant Fc-bearing fusion protein [21].
Nevertheless, in all three groups the antibody titers were
significantly higher at Day 94 post-immunization than at
Day 0 as indicated by the Student’s t-test analysis of the
mean values of Absorbance between the two time points
(P = 0.049 for scFv40, P = 0.042 for scFv69 and P < 0.001
for HER2-Fc). The specificity of the Ab1’ response in
scFv40MS and scFv69MS was confirmed by flow cytome-
try using HER2-positive SK-OV-3 and HER2-negative
CHO cells. Binding to HER2 was detected in SK-OV-3
cells incubated with scFv40MS, scFv69MS or HER2-
FcMS (Figure 1B), but not with sera of mice immunized
with PBS (NoMS). Binding was not observed following
incubation of CHO cells with any of the tested sera
(Figure 1C). These results demonstrate that in mice,
anti-idiotype immunization with trastuzumab-specific
scFv induces an anti-anti-Id Ab1’ humoral response
against the HER2 cognate antigen.
Sera from mice immunized with scFv40 and scFv69
reduce viability of SK-OV-3 cells
We then evaluated the biological activity of scFv40 and
scFv69 sera by assessing their ability to inhibit cell
growth in vitro.T ot h i se n d ,S K - O V - 3c e l l sw e r es t a b l y
transfected with a luciferase-expressing vector (CMV-
Luc-Hygro) and clone D8 was selected by limiting dilu-
tion for its high HER2 expression combined with luci-
ferase activity (SK-OV-3-Luc cells). SK-OV-3-Luc cells
were then incubated with a 1:5 dilution of scFv40MS,
scFv69MS, HER2-FcMS and NoMS for five days and
cell viability was assessed based on the level of luciferase
activity. Results were presented as the percentage of
inhibition of cell viability. Cell growth was efficiently
inhibited by scFv40MS (81% mean inhibition),
scFv69MS (92.4%) and HER2-FcMS (76.6%) but not by
NoMS (17.5%, P =0 . 0 0 2N o M Svs scFv) (Figure 2A).
These results demonstrate that HER2-specific Ab1’ anti-
bodies from sera of anti-Id scFv-immunized mice can
inhibit up to 92% of cell growth in a HER2-overexpres-
sing human cancer cell line in vitro.
Adoptive transfer of sera from mice immunized with scFv40
or scFv69 inhibits tumor growth in athymic nude mice
To evaluate in vivo the therapeutic efficiency of the anti-
HER2 Ab1’ antibodies, we injected scFv40MS, scFv69MS
or HER2-FcMS, NoMS (negative control) and trastuzu-
mab (anti-HER2 antibody, positive control) in athymic
nude mice (n = 5 for each group), which had been
grafted four days before with HER2-positive SK-OV-3-
Luc tumor cells. Tumor growth was evaluated weekly in
each group by measuring the luminescence emitted fol-
lowing luciferin injection. As expected, all mice treated
with trastuzumab or with HER2-FcMS were cured (that
is, luminescence in the surviving animals was below the
threshold level of 3 × 10
7 photons/s) at the end of the
experiment (Day 120), whereas mice treated with NoMS
were all dead by Day 45 post-challenge (Figure 2B).
Mice treated with scFv sera had a survival rate of 20%
(remission in one out five mice with scFv40MS) and
40% (remission in two out of five mice with scFv69MS)
at the end of the experiment (Day 120). Overall, the
median delay (Figure 2B) for tumors to reach the lumi-
nescence level of 3 × 10
7 photon/second was signifi-
cantly longer in mice treated with scFv69MS (66 days)
than in mice treated with NoMS (45 days, P = 0.0031).
T h eh i g h e rs u r v i v a lr a t eo fm i c et r e a t e dw i t hH E R 2 -
FcMS is in accordance with the highest titer of anti-
HER2 antibodies in HER2-FcMS than in scFv sera. Bio-
luminescence analysis of xenografted nude mice at Day
27 after challenge (corresponding to two days after the
last treatment) demonstrated smaller luminescence
patches in mice treated with scFv69MS (Figure 2D) than
in those treated with NoMS (Figure 2C). Moreover, the
two mice in remission after treatment with scFv69MS
did not present detectable bioluminescence patches.
These data clearly demonstrate the efficiency of the
HER2-specific Ab1’ antibodies from sera of anti-Id scFv-
immunized mice to in vivo inhibit growth of SK-OV-3
HER2-positive cancer cells. Altogether, these in vitro
and in vivo evidences gave us the proof of concept that
vaccination with trastuzumab-specific anti-Id scFv40 or
scFv69 generates HER2-specific Ab1’ antibodies. When
adoptively-transferred, these antibodies inhibit tumor
growth in athymic nude mice xenografted with HER2-
overexpressing cancer cells.
Prophylactic vaccination of MMTV.f.huHER2(Fo5)
transgenic mice with anti-Id scFv69 induces an anti-HER2
Ab1’ immune response followed by tumor inhibition
To further confirm the potential benefits of vaccination
by anti-Id scFv69, we performed a prophylactic vaccina-
tion experiment using the MMTV.f.huHER2(Fo5) trans-
genic mouse model [22]. This pre-clinical mouse model,
which is characterized by HER2 over-expression and
spontaneous development of mammary cancer in
females, has been validated for the study of targeted
anti-HER2 therapies such as trastuzumab [22]. Further-
m o r e ,w eh a v ep r e v i o u s l yd e t e r m i n e dt h a tM M T V . f .
huHER2(Fo5) transgenic mice are tolerant for the
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type mice, they were unable to mount a specific immu-
nological response against HER2 following vaccination
with recombinant HER2-Fc. In the present study, again
we used MMTV.f.huHER2(Fo5) mice to evaluate the
anti-HER2 response induced by immunization with PBS
alone, anti-Id scFv69 or HER2-Fc. A HER2-specific
humoral response was detected only in sera of mice
immunized with scFv69 (n =5 ,P = 0.016) (Figure 3B),
but not in sera of animals immunized with PBS (n =4 )
(Figure 3A) or with HER2-Fc (n = 5). The antibodies eli-
cited in MMTV.f.huHER2(Fo5) mice immunized with
HER2-Fc were strictly directed against the human Fc
portion of the recombinant protein (data not shown).
Furthermore, the survival curves (Figure 4A), revealed
that spontaneous mammary tumors occurred in all mice
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Page 6 of 11immunized with PBS or HER2-Fc, confirming that
MMTV.f.huHER2(Fo5) mice are tolerant for the human
HER2 antigen. Conversely, all but one of the MMTV.f.
huHER2(Fo5) mice immunized with anti-Id scFv69 were
protected from developing HER2-positive mammary
tumors throughout the experiment (14 months) (survi-
v a lr a t e=8 0 % )( F i g u r e4 A ) .F i v ea d d i t i o n a la n i m a l s
were treated with trastuzumab (200 μg/inj) (positive
control). Two out of five developed spontaneous mam-
mary tumors, in accordance with the results previously
described by Finkle et al., indicating that about 60% of
mice treated with trastuzumab did not present clinical
symptoms [22]. These results suggest a significant dis-
ease-free survival advantage for MMTV.f.huHER2(Fo5)
mice vaccinated with anti-Id scFv69 in comparison to
PBS-immunized (P = 0.0027) and HER2-Fc-immunized
mice (P = 0.0034).
To check whether anti-Id scFv vaccination could pro-
tect MMTV.f.huHER2(Fo5) females from developing
mammary tumors after the physiological changes linked
to pregnancy, we carried out a second experiment in
which females were immunized with PBS alone (n =6 ) ,
scFv40 (n =9 ) ,s c F v 6 9( n =7 )o rH E R 2 - F c( n =6 )
according to the usual protocol and then underwent
pregnancy. Protection against spontaneous mammary
tumors was observed in six (about 67%) out of nine of
the scFv40- and six (about 85%) out of seven of the
scFv69-vaccinated transgenic females, whereas PBS-
immunized or HER2-Fc-immunized mice were not pro-
tected (Figure 4B). Taken together, these results demon-
strate that prophylactic vaccination of MMTV.f.huHER2
(Fo5) transgenic mice with anti-Id scFv69 (and to a les-
ser extent with scFv40) induces an anti-HER2 Ab1’
immune response and protects mice from developing
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Page 7 of 11spontaneous HER2-positive tumors. Thus, this scFv
fragment could be considered as a potential anti-Id
based vaccine for adjuvant therapy of patients bearing
HER2-positive tumors.
Prophylactic vaccination of MMTV.f.huHER2(Fo5)
transgenic mice with anti-Id scFv69 induces scFv69-
specific Th1 and HER2-specific Th2 immune responses
To better characterize the immune response elicited by
the prophylactic vaccination, splenocytes were isolated
from PBS- or scFv69-immunized MMTV.f.huHER2(Fo5)
mice, six days after the final boost (Day 41). Stimulation
of spleen with the mitogen Concanavalin A (positive
control) induced secretion of IL2 and IFNg in superna-
tants of both PBS- and scFv69-immune splenocytes
(Table 1). The faster secretion kinetics of IL2 (24 h) and
the intermediate kinetics of IFN-gamma (48 h) are in
agreement with the kinetics observed upon activation of
T helper cell populations. Stimulation with scFv69
induced secretion of IL2 and IFN-gamma at comparable
levels only in splenocytes isolated from mice vaccinated
with anti-Id scFv69. Stimulation with HER2-Fc or the
irrelevant Mfe23-Fc and scFv13R4 did not induce any
detectable or significantly different secretion of IL2 or
IFNg (Table 1). The weak stimulation observed with the
control scFv13R4 could be due to the presence of cell
wall-derived lipopolysaccharides, which have the capa-
city to induce cytokines (Table 1). To further typify the
Th1 and Th2 immune responses induced by vaccination
with scFv69, we determined the scFv69- and HER2-spe-
c i f i ca n t i b o d yi s o t y p e sa n dt h eI g G 1 / I g G 2 ar a t i ob y
ELISA in sera from PBS- and scFv69-immunized
MMTV.f.huHER2(Fo5) mice (Figure 5). Whereas no sig-
nificant antibody response, regardless of the isotype, was
observed in sera from mice immunized with PBS (upper
panels of Figure 5), a progressively increasing anti-
scFv69 response of IgG1, IgG2a and IgG2b isotype was
observed until Day 41 (end of experiment) in sera from
mice immunized with scFv69( F i g u r e5 Al o w e rp a n e l ) .
In contrast, the HER2-specific response started only at
Day 14 until the end of the experiment and was exclu-
sively of the IgG1 isotype (Figure 5B lower panel). The
scFv69-specific IgG1/IgG2a ratio progressively decreased
during the vaccination schedule, thus confirming that,
together with IFNg/IL2 secretion, scFv69 prophylactic
vaccination of MMTV.f.huHER2(Fo5) transgenic mice
induced a scFv69-specific Th1-type immune response.
Conversely, the anti-HER2 IgG1/IgG2a ratio increased
over time (Figure 5C lower panel), demonstrating that
prophylactic vaccination of MMTV.f.huHER2(Fo5)
transgenic mice with scFV69 induced a HER2-specific
Th2-type immune response.
Discussion
Several immunotherapeutic approaches targeting HER2
have been reported in the literature, including both pas-
sive and active immunization [23]. The major problem
in the use of HER2 as a target for active immunotherapy
i st h ep r e s e n c eo fi m m u n et o l e r a n c et ot h es e l f - a n t i g e n .
The present study was conducted to assess the efficacy
of two previously selected anti-Id (Ab2) human scFv
fragments [21] to generate an active anti-HER2 immune
response. We show that vaccination with anti-Id scFv40
and scFv69 might represent a potential new therapeutic
approach for the treatment of patients with HER2-posi-
tive tumors. We also demonstrate that the in vivo anti-
tumor effects of the anti-Id scFv69 vaccine are asso-
ciated with a robust anti-HER2 humoral response
through a Th2-dependent mechanism.
First, we demonstrate that sera from scFv40- or
scFv69-immunized BALB/c mice contain Ab1’ antibo-
dies that strongly inhibit growth of SK-OV-3 cells, sug-
gesting a “trastuzumab-like” biological effect as reported
with the in vitro use of the humanized anti-HER2 tras-
tuzumab (Herceptin
®, ROCHE, Basel, Switzerland) [24].
When adoptively transferredi nn u d em i c eb e a r i n gS K -
OV-3 Luc tumor cells, these sera efficiently inhibited
tumor growth. These results provide proof of the
Table 1 Cytokine secretion in antigen-stimpulated
splenocytes from MMTV.f.huHER2(Fo5) transgenic mice
immunized with anti-idiotype scFv 69 vaccine
Cytokine Conc HER2-transgenic mouse immunized
with
Stimulating antigen (μg/ml)
PBS scFv69
Interleukin-2
Con A 7.5 356.9 ± 5.7 422.8 ± 26.5
Control scFv 13R4 2.0 <4 <4
ScFv69 2.0 <4 10.6 ± 0.8
Control Mfe23-Fc 2.0 <4 <4
HER2-Fc 2.0 <4 <4
Interferon-gamma
Con A 7.5 21.4 ± 0.9 24.2 ± 0.8
Control scFv 13R4 2.0 <1 7.0 ± 3.6
ScFv69 2.0 <1 17.0 ± 3.7
Control Mfe23-Fc 2.0 <1 <1
HER2-Fc 2.0 <1 <1
*ng/ml.
Cytokine (Il-2 and IFN-gamma) secretion in splenocytes from MMTV.f.huHER2
(Fo5) transgenic mice immunized with PBS or anti-Id scFv69. Splenocytes were
isolated on Day 42 post-immunization. Supernatants from antigen-stimulated
cells were recovered 24 h (for IL-2) and 72 h (for IFN-gamma) after in vitro
stimulation. IL-2 and IFN-gamma detection (ng/ml) were performed using an
ELISA assay, with a standard curve obtained with recombinant IL-2 (detection
limit 4 ng/ml) or recombinant IFN-gamma (detection limit 1 ng/ml). Results
are the mean ± SD of triplicate wells and are representative of two
independent experiments. Mfe23-Fc and scFv13R4 are two irrelevant antigens.
Con A, Concanavalin A.
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Page 8 of 11therapeutic potential of Ab1’ antibodies. They also
demonstrate the implication of the humoral response in
the biological effects.
Second, we show that prophylactic vaccination of both
virgin or primiparous MMTV.f.huHER2(Fo5) females
with anti-Id scFv69 induces anti-HER2 Ab1’ immune
response followed by inhibition of spontaneous develop-
ment of palpable tumors. The study by Finkle and col-
leagues indicated that early treatment with mu4D5 (the
murine version of trastuzumab) was of benefit in
MMTV.f.huHER2(Fo5)-transgenic females at high risk
of developing huHER2-positive breast tumors. Similarly,
we show that mice vaccinated with scFv69 (end of treat-
ment at six months of age) were still free of tumors at
the age of 14 months and that only one out of seven
mice immunized with anti-Id scFv69 developed a tumor.
Whereas in the work by Finkle et al. an early and pro-
longed treatment with mu4D5 was necessary to signifi-
cantly alter mammary tumor incidence and progression,
in our study, four injections of scFv69 were sufficient to
elicit almost 100% protection against mammary tumors.
Thus, different from the passive approach (mu4D5),
active immunization with a therapeutic cancer vaccine
may result in a gradual and lasting response, which
could abolish tumor development and induce a long-
term memory response leading to protection from dis-
ease recurrence.
Third, the analysis of the humoral response induced in
immunized MMTV.f.huHER2(Fo5) mice shows that
both a robust anti-scFv69 (Ab3) Th1 and an anti-HER2
(Ab1’) Th2 response were associated with the delay of
mammary tumor onset observed in animals treated with
a n t i - I ds c F v 6 9 .B a s e do nt h e s er e s u l t s ,w et h i n kt h a t
anti-Id scFv69 could efficiently be used for the long
term prevention of HER2-positive tumors via its specific
anti-HER2 Th2-dependent immune mechanism.
ScFv40 and scFv69 were isolated by phage display,
which is a relatively new technique to identify peptides
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conformational B cell epitopes [25], as it is the case for
the epitope recognized by trastuzumab [26]. The
sequence analysis of scFv40 and scFv69 revealed no
strong homology between their CDR1, 2 and 3 regions
and the regions forming the epitope recognized by tras-
tuzumab. This finding was expected as the epitope tar-
geted by trastuzumab is described to be discontinuous.
However, regarding the antigen mimicry capacity of the
scFv69 fragment, its surface characteristics should be
equivalent to those of the epitope of the selecting Ab1,
although their amino acid sequence may differ [27].
Similarly, the epitope mimics generated by Riemer et al.
[28] by phage display using trastuzumab bear no
sequence homology to HER2, but they are effective in
mimicking the HER2 antigen. Their sequence was sub-
sequently matched to the third loop of HER2 at the
HER2/trastuzumab interface using computational meth-
ods [29].
The low sequence homology between the CDR regions
of scFv40 or scFv69 and the regions forming the HER2-
e p i t o p er e c o g n i z e db yt r a s t u z u m a b[ 2 6 ]c o u l de x p l a i n
the lack of anti-HER2 Th1 response following immuni-
zation with scFv69. Indeed, anti-Id scFv are supposed to
mimic the three-dimensional rather than the primary
sequence of HER2 which is in accordance with their
anti-idiotypic nature. Furthermore, the lack of anti-
HER2 Th1 response may be beneficial since it might
balance the immunosuppressive effect of tumor-specific
regulatory T cells (Treg). Depletion or blockade of Treg
cells can lead to immune protection from tumor-asso-
ciated antigens that are expressed as self-antigens [30].
In our study, we demonstrate that scFv69-immunization
leads to a HER2-specific Th2 immune response, sug-
gesting that this type of vaccination could be effective in
cancer patients even in the presence of immunosuppres-
sive Treg cells.
Finally, cardiomyopathy has been shown to be a side
effect of trastuzumab treatment in 7% of women follow-
ing treatment with first-line anthracycline therapy and in
up to 28% of women when trastuzumab is used concur-
rently with anthracycline [31,32]. In the study by Finkle
et al., human HER2 was reported to be expressed in
heart, but no histological or clinical evidence of cardiac
or any other organ toxicity were observed following treat-
ment with mu4D5. However, these mice were not treated
with other therapeutic agents, such as anthracyclines,
before or during the study. In this context, it will be use-
ful to study the effect of immunization with scFv69 on
heart function, morphology and histology after treatment
with anthracycline and trastuzumab as we believe that
the most promising clinical application for anti-Id
scFv69-based-vaccines should be as adjuvant therapy
after treatment with chemotherapy and trastuzumab.
Indeed, integrating a targeted vaccine therapy after
induction of a major response with a monoclonal anti-
body (for example, trastuzumab) could be considered as
another therapeutic approach [33].
Conclusions
In conclusion, our results demonstrate the remarkable
efficiency of the scFv69 antibody fragment in protecting
mice from the development of HER2-positive mammary
tumors through a robust humoral response via a Th2-
dependent mechanism. These results allow us to believe
that scFv69 could be used as an anti-idiotype-based vac-
cine for adjuvant therapy in patients with HER2-positive
tumors either alone or in association with concomitant
passive infusion of trastuzumab.
Abbreviations
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HER2: human epidermal growth factor receptor 2; Id: Idiotype; IFA:
incomplete freund adjuvant; IFN-γ: interferon gamma; IL2: interleukin 2; i.p.:
intraperitoneal; PBS: phosphate-buffered saline; scFv: single chain Fragment
variable.
Acknowledgements
We thank G. Heintz and S. Bousquié for excellent technical assistance. We
also thank Genentech for providing us with the FVB-MMTV.f.huHER2(Fo5)
transgenic mice.
Author details
1IRCM, Institut de Recherche en Cancérologie de Montpellier, INSERM U896,
Université Montpellier1, CRLC Val d’Aurelle Paul Lamarque, 208 rue des
Apothicaires, Montpellier, F-34298, France.
2CRLC Val d’Aurelle-Paul
Lamarque, 35 rue de la Croix Verte, Montpellier, F-34298, France.
Authors’ contributions
MZL and TC made substantial contributions to the acquisition of data and
to analysis and interpretation of data and drafting of the manuscript. SC
made contributions to acquisition of data for the experiment of adoptive
transfer of immune sera from anti-Id scFv-vaccinated mice. VG and BR made
substantial contributions to conception, design and realization of in vivo
experiments. CBM performed statistical analysis. IAA made substantial
contributions to transgenic mice breeding and to in vivo vaccination in
those mice. JPP and AP have given final approval of the manuscript version
to be published. INT contributed to conception and design of the study,
analysis and interpretation of data, and drafting and revision of the
manuscript. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 10 September 2010 Revised: 18 January 2011
Accepted: 4 February 2011 Published: 4 February 2011
References
1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human
breast cancer: correlation of relapse and survival with amplification of
the HER-2/neu oncogene. Science 1987, 235:177-182.
2. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ,
Stuart SG, Udove J, Ullrich A, Press MF: Studies of the HER-2/neu proto-
oncogene in human breast and ovarian cancer. Science 1989,
244:707-712.
3. Nicholson RI, McClelland RA, Gee JM, Manning DL, Cannon P, Robertson JF,
Ellis IO, Blamey RW: Epidermal growth factor receptor expression in
breast cancer: association with response to endocrine therapy. Breast
Cancer Res Treat 1994, 29:117-125.
Ladjemi et al. Breast Cancer Research 2011, 13:R17
http://breast-cancer-research.com/content/13/1/R17
Page 10 of 114. Martin M, Rodriguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M,
Munarriz B, Rodriguez CA, Crespo C, de Alava E, Lopez Garcia-Asenjo JA,
Guitian MD, Almenar S, Gonzalez-Palacios JF, Vera F, Palacios J, Ramos M,
Garcia Marco JM, Lluch A, Alvarez I, Segui MA, Mayordomo JI, Anton A,
Baena JM, Plazaola A, Modolell A, Pelegri A, Mel JR, Aranda E, Adrover E,
et al: Randomized phase 3 trial of fluorouracil, epirubicin, and
cyclophosphamide alone or followed by Paclitaxel for early breast
cancer. J Natl Cancer Inst 2008, 100:805-814.
5. Disis ML, Schiffman K, Salazar LG, Almand B, Knutson KL: HER-2/neu
vaccines. Cancer Chemother Biol Response Modif 2003, 21:275-285.
6. Disis ML, Calenoff E, McLaughlin G, Murphy AE, Chen W, Groner B,
Jeschke M, Lydon N, McGlynn E, Livingston RB, Moe R, Cheever MA:
Existent T-cell and antibody immunity to HER-2/neu protein in patients
with breast cancer. Cancer Res 1994, 54:16-20.
7. Peoples GE, Goedegebuure PS, Smith R, Linehan DC, Yoshino I, Eberlein TJ:
Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize
the same HER2/neu-derived peptide. Proc Natl Acad Sci USA 1995,
92:432-436.
8. Nanda NK, Sercarz EE: Induction of anti-self-immunity to cure cancer. Cell
1995, 82:13-17.
9. Disis ML, Gooley TA, Rinn K, Davis D, Piepkorn M, Cheever MA, Knutson KL,
Schiffman K: Generation of T-cell immunity to the HER-2/neu protein
after active immunization with HER-2/neu peptide-based vaccines. J Clin
Oncol 2002, 20:2624-2632.
10. Mittendorf EA, Storrer CE, Shriver CD, Ponniah S, Peoples GE: Evaluation of
the CD107 cytotoxicity assay for the detection of cytolytic CD8+ cells
recognizing HER2/neu vaccine peptides. Breast Cancer Res Treat 2005,
92:85-93.
11. Roth A, Rohrbach F, Weth R, Frisch B, Schuber F, Wels WS: Induction of
effective and antigen-specific antitumour immunity by a liposomal
ErbB2/HER2 peptide-based vaccination construct. Br J Cancer 2005,
92:1421-1429.
12. Lollini PL, De Giovanni C, Pannellini T, Cavallo F, Forni G, Nanni P: Cancer
immunoprevention. Future Oncol 2005, 1:57-66.
13. Gritzapis AD, Mahaira LG, Perez SA, Cacoullos NT, Papamichail M,
Baxevanis CN: Vaccination with human HER-2/neu (435-443) CTL peptide
induces effective antitumor immunity against HER-2/neu-expressing
tumor cells in vivo. Cancer Res 2006, 66:5452-5460.
14. Peoples GE, Holmes JP, Hueman MT, Mittendorf EA, Amin A, Khoo S,
Dehqanzada ZA, Gurney JM, Woll MM, Ryan GB: Combined clinical trial
results of a HER2/neu (E75) vaccine for the prevention of recurrence in
high-risk breast cancer patients: U.S. military cancer institute clinical
trials group study I-01 and I-02. Clin Cancer Res 2008, 14:797-803.
15. Jerne NK: Towards a network theory of the immune system. Ann
Immunol (Paris) 1974, 125C:373-389.
16. Foon KA, John WJ, Chakraborty M, Das R, Teitelbaum A, Garrison J,
Kashala O, Chatterjee SK, Bhattacharya-Chatterjee M: Clinical and immune
responses in resected colon cancer patients treated with anti-idiotype
monoclonal antibody vaccine that mimics the carcinoembryonic
antigen. J Clin Oncol 1999, 17:2889-2895.
17. Reinartz S, Kohler S, Schlebusch H, Krista K, Giffels P, Renke K, Huober J,
Mobus V, Kreienberg R, DuBois A, Sabbatini P, Wagner U: Vaccination of
patients with advanced ovarian carcinoma with the anti-idiotype
ACA125: immunological response and survival (phase Ib/II). Clin Cancer
Res 2004, 10:1580-1587.
18. Sabbatini P, Dupont J, Aghajanian C, Derosa F, Poynor E, Anderson S,
Hensley M, Livingston P, Iasonos A, Spriggs D, McGuire W, Reinartz S,
Schneider S, Grande C, Lele S, Rodabaugh K, Kepner J, Ferrone S, Odunsi K:
Phase I study of abagovomab in patients with epithelial ovarian,
fallopian tube, or primary peritoneal cancer. Clin Cancer Res 2006,
12:5503-5510.
19. Foon KA, Lutzky J, Baral RN, Yannelli JR, Hutchins L, Teitelbaum A,
Kashala OL, Das R, Garrison J, Reisfeld RA, Bhattacharya-Chatterjee M:
Clinical and immune responses in advanced melanoma patients
immunized with an anti-idiotype antibody mimicking disialoganglioside
GD2. J Clin Oncol 2000, 18:376-384.
20. De Cerio AL, Zabalegui N, Rodriguez-Calvillo M, Inoges S, Bendandi M: Anti-
idiotype antibodies in cancer treatment. Oncogene 2007, 26:3594-3602.
21. Coelho M, Gauthier P, Pugniere M, Roquet F, Pelegrin A, Navarro-Teulon I:
Isolation and characterisation of a human anti-idiotypic scFv used as a
surrogate tumour antigen to elicit an anti-HER-2/neu humoral response
in mice. Br J Cancer 2004, 90:2032-2041.
22. Finkle D, Quan ZR, Asghari V, Kloss J, Ghaboosi N, Mai E, Wong WL,
Hollingshead P, Schwall R, Koeppen H, Erickson S: HER2-targeted therapy
reduces incidence and progression of midlife mammary tumors in
female murine mammary tumor virus huHER2-transgenic mice. Clin
Cancer Res 2004, 10:2499-2511.
23. Curigliano G, Spitaleri G, Dettori M, Locatelli M, Scarano E, Goldhirsch A:
Vaccine immunotherapy in breast cancer treatment: promising, but still
early. Expert Rev Anticancer Ther 2007, 7:1225-1241.
24. Cuello M, Ettenberg SA, Clark AS, Keane MM, Posner RH, Nau MM,
Dennis PA, Lipkowitz S: Down-regulation of the erbB-2 receptor by
trastuzumab (herceptin) enhances tumor necrosis factor-related
apoptosis-inducing ligand-mediated apoptosis in breast and ovarian
cancer cell lines that overexpress erbB-2. Cancer Res 2001, 61:4892-4900.
25. Felici F, Luzzago A, Folgori A, Cortese R: Mimicking of discontinuous
epitopes by phage-displayed peptides, II. Selection of clones recognized
by a protective monoclonal antibody against the Bordetella pertussis
toxin from phage peptide libraries. Gene 1993, 128:21-27.
26. Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW,
Leahy DJ: Structure of the extracellular region of HER2 alone and in
complex with the Herceptin Fab. Nature 2003, 421:756-760.
27. Geysen HM, Rodda SJ, Mason TJ: A priori delineation of a peptide which
mimics a discontinuous antigenic determinant. Mol Immunol 1986,
23:709-715.
28. Riemer AB, Klinger M, Wagner S, Bernhaus A, Mazzucchelli L,
Pehamberger H, Scheiner O, Zielinski CC, Jensen-Jarolim E: Generation of
Peptide mimics of the epitope recognized by trastuzumab on the
oncogenic protein Her-2/neu. J Immunol 2004, 173:394-401.
29. Riemer AB, Kraml G, Scheiner O, Zielinski CC, Jensen-Jarolim E: Matching of
trastuzumab (Herceptin) epitope mimics onto the surface of Her-2/neu–
a new method of epitope definition. Mol Immunol 2005, 42:1121-1124.
30. Kosmaczewska A, Ciszak L, Potoczek S, Frydecka I: The significance of Treg
cells in defective tumor immunity. Arch Immunol Ther Exp (Warsz) 2008,
56:181-191.
31. Crone SA, Zhao YY, Fan L, Gu Y, Minamisawa S, Liu Y, Peterson KL, Chen J,
Kahn R, Condorelli G, Ross J Jr, Chien KR, Lee KF: ErbB2 is essential in the
prevention of dilated cardiomyopathy. Nat Med 2002, 8:459-465.
32. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A,
Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L: Use of
chemotherapy plus a monoclonal antibody against HER2 for metastatic
breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792.
33. Curigliano G, Spitaleri G, Pietri E, Rescigno M, de Braud F, Cardillo A,
Munzone E, Rocca A, Bonizzi G, Brichard V, Orlando L, Goldhirsch A: Breast
cancer vaccines: a clinical reality or fairy tale? Ann Oncol 2006,
17:750-762.
doi:10.1186/bcr2826
Cite this article as: Ladjemi et al.: Vaccination with human anti-
trastuzumab anti-idiotype scFv reverses HER2 immunological tolerance
and induces tumor immunity in MMTV.f.huHER2(Fo5) mice. Breast
Cancer Research 2011 13:R17.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Ladjemi et al. Breast Cancer Research 2011, 13:R17
http://breast-cancer-research.com/content/13/1/R17
Page 11 of 11